My Profile
Edit Profile
My Follows
My Wires
My Drafts
Analytics
Email Preferences
Sign Out
home
most popular
Latest
Buy Hold Sell
Alternatives in Focus
Series
Alternatives in Focus
Buy Hold Sell
Expert Insights
Fund in Focus
Growth
Income Series
Listed Series
Livewire Live
Meet The Adviser
Meet The Investor
Outlook Series
Rapid Fire
Reporting Season
Success and More Interesting Stuff
The Pitch
The Rules of Investing
Undiscovered Funds
Views from the Top
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Weekend Report
Contributors
Find Funds
Newsletter
About Livewire
Advertising
Careers
Contact Us
Write a Wire
Notifications
Loading...
Write a wire
Account
My profile
My follows
My wires
My drafts
Analytics
Email preferences
Company
About Livewire
Advertising
Contact us
Sign out
Sign In
Join Free
Latest
Buy Hold Sell
Alternatives in Focus
Series
Alternatives in Focus
Buy Hold Sell
Fund in Focus
Growth
Income Series
Livewire Live
Meet The Investor
Rapid Fire
Reporting Season
Success and More Interesting Stuff
The Pitch
The Rules of Investing
Views from the Top
Categories
Asset Allocation
Commodities
Daily Report
Education
Equities
Fixed Income
Funds
Investment Theme
Macro
Private Assets
Property
Weekend Report
Find funds
Newsletter
life sciences
Latest news and analysis on life sciences
August 26, 2016 16:10
The Coming Boom in Life Sciences in Australia
Stuart Roberts
Pitt Street Research and NDF Research
August 26, 2016 16:10
August 22, 2016 06:29
Lifesciences: Give your portfolio a booster
shot
Buy Hold Sell
Livewire Markets
August 22, 2016 06:29
March 25, 2014 12:31
dorsaVi (ASX:DVL) is walking around with an impressive update on the commercialisation of its movement products
Matthijs Smith
Canaccord Genuity Australia
March 25, 2014 12:31
Advertisement
December 02, 2013 12:44
@morgans rate Impedimed (IPD, Outperform, Price Target A$0.30)
Livewire Equities
Livewire
December 02, 2013 12:44
November 13, 2013 10:20
@morgans have an outperform rating on Impedimed (IPD) note from Scott Power follows
Livewire Equities
Livewire
November 13, 2013 10:20
October 30, 2013 15:30
Livewire spoke with specialist Life Sciences analyst Scott Power (RBS Morgans) following the recent AusBiotech conference in Melbourne
Livewire Exclusive
Livewire Markets
October 30, 2013 15:30
61-66 of 66
1
2
3
4
most
popular
Equities
Buy Hold Sell: The photo finish - 5 ASX stock duels that could go either
way
Buy Hold Sell,
Livewire Markets
Equities
Buy Hold Sell: 5 ASX stayers built to go the
distance
Buy Hold Sell,
Livewire Markets
Equities
Buy Hold Sell: 3 ASX stocks built to handle tough
conditions
Buy Hold Sell,
Livewire Markets
Equities
“The world has gone mad”: Marcus Padley goes 100% cash
Vishal Teckchandani,
Livewire Markets
view all
Advertisement
